pGy2 program
HEMATOLOGY/ONCOLOGY

Residency Program Director
  • Megan Hinkley, PharmD, BCOP

    • Clinical Specialist Pharmacist, Oncology
    • PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
    • PharmD- University of Michigan
    • PGY1- Indiana University Health
    • PGY2 Oncology- Indiana University Health
    Contact
Previous Year Residents
  • Ryan DasGupta

    Clinical Specialist Pharmacist-Outpatient Breast Cancer, The James Cancer Hospital at The Ohio State University
  • Carlo Legasto

    Clinical Specialist Pharmacist-Oncology Float, The James Cancer Hospital at The Ohio State University
  • M. Alexandra Schickli

    Clinical Specialist Pharmacist-Oncology Float, The James Cancer Hospital at The Ohio State University
  • Filiz Yucebay

    Clinical Specialist Pharmacist-Hematology Float, The James Cancer Hospital at The Ohio State University
  • Christina Matthews

    Clinical Specialist, Roswell Park Cancer Institute
  • Anli McCoy

    Oncology Clinical Pharmacy Specialist, The Christ Hospital
  • Nahir Rivera-Robles

    Outpatient Breast Clinical Pharmacist, Moffitt Cancer Center
  • Ally Waller

    Clinical Specialist Pharmacist, Hematology, The James Cancer Hospital at The Ohio State University

About the PGY2 Hematology/ Oncology Residency Program

Purpose

PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in advanced or specialized practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge incorporating both into the provision of patient care that improves medication therapy. Residents who successfully complete an accredited PGY2 pharmacy residency should possess competencies that qualify them for clinical pharmacist and/or faculty positions and position them to be eligible for attainment of board certification in that practice area (when board certification for the practice area exists).

The purpose of the PGY2 Hematology/Oncology residency is to develop specialized knowledge in the pathophysiology and management of patients with hematology and oncology disorders. This is accomplished through core rotations to strengthen hematology and oncology fundamentals as well as elective rotations with the flexibility to meet the individual’s needs.

The program is designed to develop the resident’s clinical expertise and additionally provide opportunities for teaching, research, and quality improvement. Pharmacists completing the residency will be trained as clinical specialists able to excel as an independent practitioner. The goal of the program is to become an integral member of a Hematology/Oncology multidisciplinary team in a large academic setting.

DSC_8758Residency Sites

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital is ranked nationally as one of the top hospitals for cancer care, maintaining an “exceptional” rating – the highest descriptor given by the National Cancer Institute, and is the third largest cancer center in the nation. Recently opened in December 2014, with 21 floors spanning 1.1 million square feet, the new James Cancer Hospital and Solove Research Institute revolutionizes the way cancer prevention and care are provided, with over 200 specialized oncologists and cancer researchers working side-by-side to unlock the mysteries of what causes cancer and, using those discoveries, transition from cancer treatment to cancer prevention.

Read More

DSC_8683

This 308-bed adult cancer clinical care facility, including a 36-bed blood and marrow transplant unit, is a member of the National Comprehensive Cancer Network, the National Cancer Institute’s National Clinical Trial Network— notably one of only four centers funded by the NCI to conduct both Phase I and II clinical trials on novel anticancer drugs, achieved Magnet® designation for excellence in patient care, and is fully accredited by the Joint Commission, the American College of Surgeons Common on Cancer and the Foundation for the Accreditation of Cellular Therapy. The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.

The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our subspecialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their subspecialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skillset necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.

KEY ROTATIONS/EXPERIENCES

The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.

  • Inpatient Acute Leukemia
  • Bone Marrow Transplantation
  • Inpatient Benign Hematology and Lymphoma/Myeloma
  • Inpatient Oncology
  • Outpatient Hematology Clinics
    • Benign Hematology
    • Lymphoma
    • Myeloma
    • BMT and Acute Leukemia
  • Outpatient Oncology Clinics
    • Breast Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Genitourinary Cancer
    • Head & Neck/Sarcoma
    • NeuroOncology
    • Melanoma
  • Other Outpatient Clinics
    • Oncology Anticoagulation
    • Clinical Trials Unit
  • Pain and Palliative Care
  • Investigational Drug Service
  • Oncology Administration
  • Informatics
  • Teaching
  • Infectious Disease
  • Medication Safety

Key Preceptors

Learn more about the Hematology/Oncology key preceptors:

Read More

INPATIENT/OUTPATIENT HEMATOLOGY

Hallie Barr, PharmD, BCOP
Outpatient Hematology/Oncology
Clinical Trials Unit

Jessica Dempsey, PharmD, BCOP
Outpatient Multiple Myeloma

Emily Dotson, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Lindsay Hazelden, PharmD
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Dan Kendzierski, PharmD
Outpatient Hematology/Oncology

Miryoung Kim, PharmD, BCOP
Inpatient BMT and Acute Leukemia

Jordan Lundberg, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Marcin Puto, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia

Julianna Roddy, PharmD, BCOP
Inpatient/Outpatient BMT and Acute Leukemia

Ally Waller, PharmD
Hematology Float

Tracy Wiczer, PharmD, BCOP
Inpatient/Outpatient Benign Hematology, Chronic Lymphocytic Leukemia, and Lymphoma

Kiersten Williams, PharmD
Outpatient BMT and Acute Leukemia

Sherry Williams, PharmD, BCOP
Inpatient BMT and Acute Leukemia

Filiz Yucebay, PharmD
Hematology Float

INPATIENT/OUTPATIENT ONCOLOGY

Matt Arango, PharmD, BCOP
Outpatient Gastrointestinal Cancer

Michael Berger, PharmD, BCOP
Outpatient Breast Cancer

Ryan DasGupta, PharmD
Outpatient Breast Cancer

Megan Hinkley, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Genitourinary Cancers

Sarah Hoffman, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Head & Neck Cancer/Sarcoma

Carlo Legasto, PharmD
Oncology Float

Jill Mutziger, PharmD
Inpatient Medical Oncology

Josh Reardon, PharmD, BCOP
Outpatient Gastrointestinal Cancer

M. Alexandra Schickli, PharmD
Oncology Float

Tom Schultz, PharmD
Inpatient Medical Oncology/Outpatient Head & Neck Cancer/Sarcoma

Michael Smith, PharmD, BCOP
Outpatient Lung Cancer

Craig Vargo, PharmD, BCOP
Outpatient Breast Cancer

Sherry Vogt, PharmD, BCOP
Inpatient Medical Oncology/Outpatient Genitourinary Cancers

HEMATOLOGY/ONCOLOGY ANTICOAGULATION

Aaron Dush, PharmD, CACP
Hematology/Oncology Anticoagulation

Paige Erdeljac, PharmD, BCACP
Hematology/Oncology Anticoagulation

Stephanie Yager, PharmD
Hematology/Oncology Anticoagulation

PAIN AND PALLIATIVE MEDICINE

Stephanie Abel, PharmD, BCPS
Palliative Medicine

Justin Kullgren, PharmD, CPE
Palliative Medicine

Maureen Saphire, PharmD, CGP, CDP
Palliative Medicine

OTHER HEMATOLOGY AND ONCOLOGY PRECEPTORS

Amber Hartman, PharmD
Medication Safety

Ming Poi, PharmD
Clinical Translational Research

ADMINISTRATION

Janinah Barretto, PharmD, MS
Pharmacy Manager
Oncology Informatics

Mitch Dorn, PharmD
Pharmacy Manager
Inpatient Operations

Michael Ganio, PharmD, MS, BCPS, CPHIMS
Pharmacy Manager
Outpatient Infusion and Operations

Sarah Hudson-Disalle, PharmD
Pharmacy Manager
Medication Assistance

Julie Kennerly, PharmD, MS, MHA, BCPS
Assistant Director of Pharmacy
Clinical and Specialty Pharmacy Services

Ben Lopez, PharmD, MS, MHA, BCPS
Associate Director of Pharmacy
Inpatient Operations and Compliance

Ryan Naseman, PharmD, MS, BCPS
Assistant Director of Pharmacy
Outpatient Infusion and Operations

Stephen Polley, PharmD
Pharmacy Manager
Investigational Drugs Services

Selected RESIDENT RESEARCH

  • Romidepsin for the treatment of relapsed and refractory T-Cell lymphomas: A single-center experience.  Legasto C, Hwang S, Li J, Waller A, Dotson E, William B, Porcu P.
  • Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. DasGupta R, Levine L, Wiczer T, Cataland S.
  • Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.  Schickli M, Berger M, Lustberg M, Vargo C.
  • Tocilizumab for first-line therapy for steroid-refractory acute graft-versus-host-disease: Analysis of a single-center experience.  Yucebay F, Puto M, Matthews C, Yildiz V, Wei L, Devine S, Efebera Y, Roddy J. 
  • Retrospective Review of Neoadjuvant Split-dose Cisplatin plus Gemcitabine for Patients with Urothelial Carcinomas of the Bladder and Upper Tract Dempsey J, Hinkley M, Mori Vogt S, Lundberg J, Mortazavi A.
  • Characterization of Pemetrexed Toxicity in Patients with Renal Insufficiency Hill J, Vargo C, Smith M, Streeter J, Carbone D.
  • A comparison of decitabine-associated toxicities in patients with and without renal impairment Levine L, Roddy J, Kim M, Phillips G, Walker A.
  • Gemcitabine and liposomal doxorubicin for relapsed refractory T cell lymphomas. Waller A, Lundberg J, Dotson E, Porcu P.
  • pCR rates with pertuzumab + trastuzumab as neoadjuvant therapy in breast cancer. Matthews C, Berger M, Vargo C, Lustberg M.
  • ATG dose and immune reconstitution after Flu/Bu/ATG prep for reduced intensity allogeneic transplant. Rivera-Robles N, Puto M, Roddy J, Devine S.
  • FLA vs MEC in relapsed refractory AML. McCoy A, Williams S, Kim M, Bhatnagar B.

Benefits and Additional Requirements

Application Deadline:  January 2, 2018

Start Date: July 2, 2018

Annual Salary – $47,500

Vacation Days – 10 Days

Staffing Requirement – 20 weekends per year

Completion of a Major Research Project

TEACHING OPPORTUNITIES

Download PDF